The Experts below are selected from a list of 28506 Experts worldwide ranked by ideXlab platform
Garry E Gold - One of the best experts on this subject based on the ideXlab platform.
-
applications of pet mri in Musculoskeletal Disease
Journal of Magnetic Resonance Imaging, 2018Co-Authors: Feliks Kogan, Stephen M Broski, Daehyun Yoon, Garry E GoldAbstract:New integrated PET-MRI systems potentially provide a complete imaging modality for diagnosis and evaluation of Musculoskeletal Disease. MRI is able to provide excellent high-resolution morphologic information with multiple contrast mechanisms that has made it the imaging modality of choice in evaluation of many Musculoskeletal disorders. PET offers incomparable abilities to provide quantitative information about molecular and physiologic changes that often precede structural and biochemical changes. In combination, hybrid PET-MRI can enhance imaging of Musculoskeletal disorders through early detection of Disease as well as improved diagnostic sensitivity and specificity. The purpose of this article is to review emerging applications of PET-MRI in Musculoskeletal Disease. Both clinical applications of malignant Musculoskeletal Disease as well as new opportunities to incorporate the molecular capabilities of nuclear imaging into studies of nononcologic Musculoskeletal Disease are discussed. Lastly, we discuss some of the technical considerations and challenges of PET-MRI as they specifically relate to Musculoskeletal Disease. Level of evidence 5 TECHNICAL EFFICACY: Stage 3 J. Magn. Reson. Imaging 2018;48:27-47.
-
potential of pet mri for imaging of non oncologic Musculoskeletal Disease
Quantitative imaging in medicine and surgery, 2016Co-Authors: Feliks Kogan, Audrey P Fan, Garry E GoldAbstract:Early detection of Musculoskeletal Disease leads to improved therapies and patient outcomes, and would benefit greatly from imaging at the cellular and molecular level. As it becomes clear that assessment of multiple tissues and functional processes are often necessary to study the complex pathogenesis of Musculoskeletal disorders, the role of multi-modality molecular imaging becomes increasingly important. New positron emission tomography-magnetic resonance imaging (PET-MRI) systems offer to combine high-resolution MRI with simultaneous molecular information from PET to study the multifaceted processes involved in numerous Musculoskeletal disorders. In this article, we aim to outline the potential clinical utility of hybrid PET-MRI to these non-oncologic Musculoskeletal Diseases. We summarize current applications of PET molecular imaging in osteoarthritis (OA), rheumatoid arthritis (RA), metabolic bone Diseases and neuropathic peripheral pain. Advanced MRI approaches that reveal biochemical and functional information offer complementary assessment in soft tissues. Additionally, we discuss technical considerations for hybrid PET-MR imaging including MR attenuation correction, workflow, radiation dose, and quantification.
Charlotte Salter - One of the best experts on this subject based on the ideXlab platform.
-
impact of health literacy in patients with chronic Musculoskeletal Disease systematic review
PLOS ONE, 2012Co-Authors: Yoon K Loke, Ina Hinz, Xia Wang, Gill Rowlands, David G I Scott, Charlotte SalterAbstract:To estimate the prevalence of low health literacy, and evaluate the impact of low health literacy on outcomes in patients with chronic Musculoskeletal conditions.
Marissa Lassere - One of the best experts on this subject based on the ideXlab platform.
-
Power Doppler ultrasound in Musculoskeletal Disease: a systematic review.
Seminars in arthritis and rheumatism, 2006Co-Authors: Fredrick Joshua, John Edmonds, Marissa LassereAbstract:Objective To evaluate the performance characteristics of power Doppler ultrasound as a diagnostic and monitoring tool in the assessment of Musculoskeletal Disease through a systematic review of the literature. Methods Search Strategy: We performed a literature search of PUBMED (1966 to June 2005). Selection Criteria: Only original research reports written in English involving Musculoskeletal Disease and power Doppler ultrasound were included. Reviews were noted but not included. Data Extraction/Reporting: The design, subjects, methods, imaging protocols, and performance characteristics studied in the research papers were reported. Results Of 3568 identified reports, 139 involved power Doppler ultrasound of the Musculoskeletal system. Fifty-three of these reports met the inclusion criteria. Ultrasound machine settings were specified in 63% of reports. Rheumatoid arthritis was the most commonly studied Musculoskeletal Disease (64% of papers). Validity was the most studied performance characteristic (94% of reports), while reliability and responsiveness were studied in 17 and 34%, respectively. Conclusions Although the majority of research reports of power Doppler ultrasound assessment of the Musculoskeletal system evaluated validity, less than half reported reliability and responsiveness. Further work is needed to evaluate power Doppler ultrasound assessment of the Musculoskeletal system before it can be used to guide clinical decisions or be used as an endpoint in clinical trials.
Philip J Mease - One of the best experts on this subject based on the ideXlab platform.
-
international patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials
Annals of the Rheumatic Diseases, 2017Co-Authors: Anamaria Orbai, Philip J Mease, Laure Gossec, Maarten De Wit, Judy A Shea, Ying Ying Leung, William Tillett, Musaab Elmamoun, Kristina Callis Duffin, Willemina CampbellAbstract:Objective To identify a core set of domains (outcomes) to be measured in psoriatic arthritis (PsA) clinical trials that represent both patients9 and physicians9 priorities. Methods We conducted (1) a systematic literature review (SLR) of domains assessed in PsA; (2) international focus groups to identify domains important to people with PsA; (3) two international surveys with patients and physicians to prioritise domains; (4) an international face-to-face meeting with patients and physicians using the nominal group technique method to agree on the most important domains; and (5) presentation and votes at the Outcome Measures in Rheumatology (OMERACT) conference in May 2016. All phases were performed in collaboration with patient research partners. Results We identified 39 unique domains through the SLR (24 domains) and international focus groups (34 domains). 50 patients and 75 physicians rated domain importance. During the March 2016 consensus meeting, 12 patients and 12 physicians agreed on 10 candidate domains. Then, 49 patients and 71 physicians rated these domains9 importance. Five were important to >70% of both groups: Musculoskeletal Disease activity, skin Disease activity, structural damage, pain and physical function. Fatigue and participation were important to >70% of patients. Patient global and systemic inflammation were important to >70% of physicians. The updated PsA core domain set endorsed by 90% of OMERACT 2016 participants includes Musculoskeletal Disease activity, skin Disease activity, pain, patient global, physical function, health-related quality of life, fatigue and systemic inflammation. Conclusions The updated PsA core domain set incorporates patients9 and physicians9 priorities and evolving PsA research. Next steps include identifying outcome measures that adequately assess these domains.
-
development of simple clinical criteria for the definition of inflammatory arthritis enthesitis dactylitis and spondylitis a report from the grappa 2014 annual meeting
The Journal of Rheumatology, 2015Co-Authors: Philip J Mease, Jane J Park, Amit Garg, Dafna D Gladman, Philip S HelliwellAbstract:Rheumatologists are trained to determine the presence of Musculoskeletal inflammation through history, physical examination, and if needed, laboratory tests and imaging. However, primary care clinicians, dermatologists, surgeons, and others who may initially see patients with Musculoskeletal pain are not necessarily able to make the distinction between inflammatory (e.g., rheumatoid arthritis or psoriatic arthritis) and noninflammatory Disease (osteoarthritis, traumatic or degenerative tendonitis, back pain, or fibromyalgia). If such clinicians could more readily suspect and identify possible inflammatory Musculoskeletal Disease, it would lead to more timely diagnosis and triage to rheumatologists for diagnosis and appropriate management. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has been developing evidence-based, practical and reliable criteria that can be used by clinicians to identify inflammatory Musculoskeletal Disease. The research initiative involves a sequential process of expert clinician nominal group technique, patient focus groups, and Delphi exercises to identify core definitive features of inflammatory Disease. The goal is to develop simple clinical criteria (history and physical examination elements) to identify inflammatory arthritis, enthesitis, dactylitis, and spondylitis and distinguish these from degenerative, mechanical, or other forms of these conditions, to achieve more timely and accurate diagnosis and referral of patients with inflammatory arthritis.
-
development of simple clinical criteria for the definition of inflammatory arthritis enthesitis dactylitis and spondylitis a report from the grappa 2012 annual meeting
The Journal of Rheumatology, 2013Co-Authors: Philip J Mease, Amit Garg, Dafna D Gladman, Philip S HelliwellAbstract:Dermatologist and primary care clinicians are in an ideal position to identify the emergence of psoriatic arthritis (PsA) in patients with psoriasis. Yet these clinicians are not well trained to distinguish inflammatory Musculoskeletal Disease from other more common problems such as osteoarthritis, traumatic or degenerative tendonitis and back pain, or fibromyalgia. A simple set of clinical criteria to identify inflammatory Disease would aid recognition of PsA. At its 2012 annual meeting, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) discussed development of evidence-based, practical, and reliable definitions of inflammatory arthritis, enthesitis, dactylitis, and spondylitis. This project will be a sequential process of expert clinician nominal-group technique, patient surveys and focus groups, and Delphi exercises to identify core features of inflammatory Disease, testing these in a small group of patients with and without inflammatory Disease, and finally validating these criteria in larger groups of patients.
-
distinguishing inflammatory from noninflammatory arthritis enthesitis and dactylitis in psoriatic arthritis a report from the grappa 2010 annual meeting
The Journal of Rheumatology, 2012Co-Authors: Philip J MeaseAbstract:The most widely applied criteria for classifying psoriatic arthritis (PsA) are the CASPAR (ClASsification of Psoriatic ARthritis) criteria. A patient who fulfills the CASPAR criteria must have evidence of inflammatory arthritis, enthesitis, or spondylitis, and may have an inflammatory Musculoskeletal component, dactylitis. Although the criteria were developed by rheumatologists, not all patients with PsA are seen by rheumatologists. Thus, it is important for clinicians such as dermatologists, primary care providers, physiatrists, and orthopedists, and patients themselves, to be able to recognize the presence of inflammatory Musculoskeletal Disease and distinguish it from degenerative or traumatic Musculoskeletal Disease. At their 2010 annual meeting, members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) discussed the steps they are taking to define the key variables that must be present to distinguish inflammatory arthritis, enthesitis, and dactylitis from degenerative, traumatic, mechanical, or infectious forms of these conditions.
Paul Emery - One of the best experts on this subject based on the ideXlab platform.
-
power doppler sonography improving Disease activity assessment in inflammatory Musculoskeletal Disease
Arthritis & Rheumatism, 2003Co-Authors: Richard J Wakefield, Andrew K Brown, Philip Oconnor, Paul EmeryAbstract:Musculoskeletal ultrasonography (US) is a powerful tool for evaluating joint and soft tissue pathology and is fast becoming an integral part of routine diagnosis and management in rheumatology practice (1–6). This imaging technique is now being performed by rheumatologists, particularly in Europe, as part of their standard clinical assessment of patients. Increasing evidence supports the use of US in a variety of different locations with demonstrable advantage over standard clinical assessment, enabling more accurate patient diagnosis and facilitating the most appropriate management decisions (7). The trend toward earlier aggressive therapy for inflammatory Musculoskeletal Disease requires reliable initial diagnosis and optimal Disease activity assessment. Interest has therefore been directed toward the use of US as an objective tool for the detection and monitoring of joint and soft tissue inflammation and bone damage (8–15) in early Disease. US has a number of advantages over other imaging techniques. It is safe, noninvasive, and emits no ionizing radiation. The equipment can be situated in the rheumatology outpatient clinic, improving patient access and enabling rapid, “real-time” dynamic examinations of multiple joints in multiple planes at one sitting. In addition, both the capital and running costs of US are significantly lower than those of other imaging modalities, such as magnetic resonance imaging (MRI) and computed tomography (CT). Traditional gray-scale US has been successfully used for some time for the detection of joint and soft tissue inflammation (1–15). More recently, additional US techniques, including Doppler, have been introduced, offering the potential for improving the accuracy of a US assessment. Doppler US is a technique for making noninvasive measurements of blood flow and was developed from the principles first described by Austrian physicist Christian Doppler in 1842 (16). He was the first to observe the effect of motion on sound when he detected a change in the frequency of a sound wave as a result of movement of either its source or receiver. There are two main types of Doppler US, color flow Doppler (CFD) and power Doppler (PDS). Both produce a similar color spectral map superimposed onto the gray-scale image (the colors being related to the difference in frequency between the transmitted sound wave and that reflected from the moving interface [the Doppler frequency shift]), but they actually encode different information. CFD represents an estimate of the mean Doppler frequency shift and relates to velocity and direction of red blood cells, whereas PDS denotes the amplitude of the Doppler signal, which is determined by the volume of blood present. In this way, CFD is better suited for evaluating high-velocity flow in large vessels (e.g., carotids), whereas PDS is better suited for assessing low-velocity flow in small vessels (e.g., synovium). There are a number of particular advantages for using PDS in Musculoskeletal assessment. Because PDS provides increased sensitivity to low-volume, lowvelocity blood flow at the microvascular level, it is particularly useful for measuring and detecting changes Dr. Brown is an Arthritis Research Campaign (ARC) Research Fellow. Dr. Emery is an ARC Professor of Rheumatology. Richard J. Wakefield, MRCP, Andrew K. Brown, MRCP, Paul Emery, MD, MA, MB, FRCP: University of Leeds, Leeds, UK; Philip J. O’Connor, FRCR: Leeds General Infirmary, Leeds, UK. Address correspondence and reprint requests to Paul Emery, MD, MA, MB, FRCP, Academic Unit of Musculoskeletal Disease, Department of Rheumatology, Leeds General Infirmary, Leeds LS1 3EX, UK. E-mail: p.emery@leeds.ac.uk. Submitted for publication November 5, 2002; accepted November 6, 2002. Arthritis & Rheumatism
